Copyright
©The Author(s) 2022.
World J Clin Cases. May 6, 2022; 10(13): 4110-4118
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.4110
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.4110
Table 1 Baseline characteristics of patients allocated to the Xuebijing injection and control (saline) groups
Saline group (n = 30) | XBJ group (n = 30) | P value | |
Age (yr) | 57.4 ± 5.3 | 56.8 ± 6.2 | 0.69 |
Male | 18 | 20 | |
Weight (kg) | 63.6 ± 5.8 | 65.4 ± 5.6 | 0.22 |
Diabetes mellitus (n) | 5 | 7 | 0.44 |
Preoperative LVEF (%) | 51.7 ± 8.5 | 52.5 ± 7.6 | 0.71 |
Ejection fraction | 50.2 ± 3.2 | 50.3 ± 3.8 | 0.91 |
Preoperative medications (n) | |||
β-blockers | 8 | 6 | 0.54 |
Calcium channel blockers | 5 | 7 | 0.52 |
Renin angiotensin system inhibitors | 5 | 3 | 0.44 |
Statin | 4 | 2 | 0.39 |
Digoxin | 6 | 8 | 0.54 |
Diuretics | 16 | 19 | 0.43 |
Surgical procedure (n) | |||
Aortic valve replacement | 8 | 11 | 0.40 |
Mitral valve replacement | 10 | 9 | 0.78 |
Tricuspid annuloplasty | 12 | 10 | 0.59 |
Pulmonary function test | |||
FVC; % predicted | 82.8 ± 7.4 | 81.9 ± 8.1 | 0.65 |
Operation time (min) | 257 ± 38 | 271 ± 41 | 0.17 |
CPB time (min) | 104 ± 31 | 111 ± 27 | 0.35 |
Intraoperative fluid balance (mL) | 2138 ± 348 | 2215 ± 387 | 0.42 |
Table 2 Comparison of postoperative outcomes between the Xuebijing injection and control (saline) groups
Saline group (n = 30) | XBJ group (n = 30) | P value | |
Ejection fraction (day 2) | 42.2 ± 2.7 | 46.3 ± 3.7 | 0.001 |
Mechanical ventilation time (h) | 10.5 ± 2.6 | 8.9 ± 1.7 | 0.006 |
Length of ICU stay (h) | 31.6 ± 5.2 | 28.9 ± 4.4 | 0.034 |
Time from surgery to discharge (d) | 12.5 ± 3.8 | 10.7 ± 2.6 | 0.032 |
ARDS (n) | 3 | 4 | 0.687 |
Table 3 Comparison of dynamic changes in respiratory function and inflammation- and oxidative stress-related markers during the perioperative periods between the Xuebijing injection and control groups
Group | Baseline | 0 h | 12 h | 24 h | 48 h | |
PaO2/FiO2 | Saline | 398.40 ± 22.66 | 361.92 ± 48.62 | 258.93 ± 39.03 | 320.64 ± 46.43 | 341.44 ± 35.28 |
XBJ | 387.12 ± 35.77 | 358.48 ± 39.21 | 289.40 ± 44.07a | 353.34 ± 31.54a | 379.08 ± 22.54a | |
CK-MB | Saline | 0.26 ± 0.07 | 0.71 ± 0.12 | 2.74 ± 0.48 | 4.25 ± 0.83 | 1.95 ± 0.62 |
XBJ | 0.26 ± 0.08 | 0.58 ± 0.12 | 2.27 ± 0.33a | 3.02 ± 0.44a | 1.09 ± 0.37a | |
TnI | Saline | 0.02 ± 0.01 | 1.45 ± 0.28 | 8.01 ± 1.13 | 13.03 ± 2.56 | 4.03 ± 0.92 |
XBJ | 0.02 ± 0.01 | 1.38 ± 0.93 | 4.77 ± 0.76a | 8.29 ± 1.73a | 3.16 ± 0.43a | |
TNF-α | Saline | 13.51 ± 4.19 | 71.18 ± 29.21 | 147.36 ± 43.84 | 226.31 ± 60.22 | 122.48 ± 55.18 |
XBJ | 15.61 ± 4.51 | 70.69 ± 27.24 | 125.64 ± 34.44a | 173.61 ± 40.03a | 99.96 ± 33.37a | |
IL-1β | Saline | 16.98 ± 4.14 | 32.95 ± 9.05 | 92.31 ± 18.45 | 78.43 ± 17.54 | 62.71 ± 15.40 |
XBJ | 13.13 ± 4.22 | 28.23 ± 6.24 | 77.25 ± 9.16a | 66.15 ± 12.18a | 43.60 ± 13.33a | |
IL-8 | Saline | 831.36 ± 136.86 | 1002.73 ± 180.26 | 1530.90 ± 235.96 | 1400.83 ± 268.85 | 1134.86 ± 211.41 |
XBJ | 767.30 ± 155.86 | 960.43 ± 187.49 | 1369.93 ± 244.21a | 1251.76 ± 240.81a | 984.86 ± 184.43a | |
IL-10 | Saline | 90.60 ± 15.82 | 121.96 ± 18.15 | 167.41 ± 18.54 | 152.53 ± 33.94 | 121.26 ± 20.73 |
XBJ | 87.27 ± 20.83 | 123.30 ± 18.31 | 176.72 ± 27.91 | 166.97 ± 21.94a | 131.87 ± 19.52a | |
MDA | Saline | 0.11 ± 0.08 | 0.49 ± 0.19 | 0.14 ± 0.09 | 0.11 ± 0.08 | 0.11 ± 0.10 |
XBJ | 0.09 ± 0.04 | 0.31 ± 0.12a | 0.13 ± 0.11 | 0.10 ± 0.06 | 0.10 ± 0.04 | |
8-Isoprostane | Saline | 1.84 ± 0.46 | 8.31 ± 0.76 | 6.29 ± 0.75 | 3.25 ± 0.52 | 1.83 ± 0.36 |
XBJ | 2.00 ± 0.55 | 6.63 ± 0.88a | 6.29 ± 0.75 | 3.24 ± 0.51 | 1.84 ± 0.53 |
- Citation: Jin ZH, Zhao XQ, Sun HB, Zhu JL, Gao W. Effect of Xuebijing injection on myocardium during cardiopulmonary bypass: A prospective, randomized, double blind trial. World J Clin Cases 2022; 10(13): 4110-4118
- URL: https://www.wjgnet.com/2307-8960/full/v10/i13/4110.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i13.4110